Cheetah Medical, a provider of non-invasive hemodynamic monitoring systems, has secured an initial investment of $5m from HighCape Partners.
HighCape Partners is a firm co-founded by Kevin Rakin, who joined Cheetah Medical’s board of directors in 2013.
This investment from HighCape is an extension of the previously announced $9m fundraising round, which closed in February 2014.
Cheetah Medical has developed the Cheetah Nicom hemodynamic management system. Based on the company’s proprietary bioreactance technology, the Cheetah Nicom offers a completely non-invasive means to measure key hemodynamic parameters. The system is currently available in more than 60 countries, including the US.
Cheetah Medical president and CEO Chris Hutchison said that the company believes that its technology has the potential to bring significant value to clinicians and other healthcare providers in the ICU, operating room and emergency department by driving fundamental improvements in patient monitoring.
"This additional capital will fund the continued expansion of our sales and marketing activities in the US and internationally. We are grateful for the continued support of our investors and excited to add HighCape to that list," Hutchison added.